LOVE Pharma Co. provide the following update on the advancement of the previously announced trial focused upon clinical applications for psilocybin assisted therapy for addiction to be conducted at Johns Hopkins. The study will be led by Dr. Albert Garcia-Romeu and will help to establish consumer confidence and guide the development and use of psilocybin products for addiction treatment.

Albert Garcia-Romeu, Ph.D. is a member of the Psychiatry and Behavioral Sciences faculty at the Johns Hopkins University School of Medicine, where he studies the effects of psychedelic drugs in humans, with a focus on psilocybin as an aid in the treatment of addiction. MicroDoz Therapy is sponsoring a study to test the effectiveness of psilocybin in treating Cannabis Use Disorder in 12 patients. The proposed study timeline includes the following, which is subject to potential changes.

Final regulatory approval and hiring of study coordinator - October-November. Initial patient recruitment - December-January. Complete patient treatment - First Quarter 2024.

Complete follow-ups - Q2-Q3 2024. Data generated in the study will be available to MicroDoz Therapy Inc., a wholly owned subsidiary of Love Pharma. LOVE is excited to officially launch this research initiative at Johns Hopkins this Fall and will continue to update shareholders as milestones are achieved (for which there is no guarantee).

Sponsoring a successful pilot trial will allow the company to advance further clinical research initiatives.